You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
sHLA Protein Chip
SBC: GENOMICS USA, INC. Topic: NIAIDAbstract: “sHLA Protein Chip” The class I [A, B, C] and class II HLA proteins [DRB1, DQ, DP] comprise the heart of the inducible human immune system. For organ, marrow and stem cell transplantation, the development of serum-born antibodies against one or more of those many HLA proteins comprises the best and earliest test for transplant rejection. Because of the enormous medical importance of ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
A near-real-time electromagnetic data-link for geothermal downhole instruments
SBC: E-Spectrum Technologies, Inc. Topic: 16aThere exists a need to obtain near-real-time information in a wireless tool configuration to be used in dynamic geothermal well conditions, such as when drilling is in progress. A tool which can provide this near real-time information from sensors located near the bit of the drill string will help reduce the hazards and costs associated with geothermal well development by allowing surface monitori ...
SBIR Phase II 2018 Department of Energy -
Graphene Backing for Radioisotope Targets
SBC: APPLIED NANOTECH, INC. Topic: 26eFor nuclear physics research, thin film isotopic specialty targets are often requested for the use and in charged-particle-induced experiments. There are also tens of radioisotopes that are of interest for medical imaging, industrial and R&D uses. The targets of interest include B, O, Si, and Cr; isotopes of refractory metals, such as Re, Os, Ir are good examples. However, many of the isotopes can ...
SBIR Phase II 2018 Department of Energy -
Hardening of DOE UQ Codes for Ultra-Deep Proactive Geosteering in Oilfield Service
SBC: CYENTECH CONSULTING LLC Topic: 02bMost of future oil and gas exploration and production will be moving into more challenging environments and directional drilling is an essential technique for tapping the “difficult” oil and gas deposits. As the key technology that enables directional drilling, geosteering is the act of adjusting the well trajectory on the fly. The goal of geosteering is to increase production, reduce cost and ...
SBIR Phase II 2018 Department of Energy -
Rapid Assessment of Distribution Line Damage via Autonomous UAV
SBC: BRAINS4DRONES LLC Topic: 05bTwo-thirds of all electric outage minutes are weather-related, mostly the result of damage to above ground distribution lines. These outages cost the U.S. economy between $18 and $33 billion per year. We propose to rapidly assess line damage immediately following an extreme weather event using specially equipped unmanned aerial vehicles (UAVs). Efforts to restore power start with the utility’s s ...
SBIR Phase II 2018 Department of Energy -
Free Piston Linear Motor Whole Air Compressor for Treaty Monitoring
SBC: KAI, LLC Topic: 04aUnder the Department of Energy’s Ground-based Nuclear Detonation Research and Development (GNDD R&D) Program, the Air Force Technical Application’s Center (AFTAC) monitors for nuclear explosions through high altitude whole-air gas sampling using compressors to inject air into a high-flow air stream or store in a high-pressure vessel. The existing compressors have proven reliability issues with ...
STTR Phase II 2018 Department of Energy -
Topic 346: Targeted Radionuclide Therapy of Neuroendocrine Tumors Using 212Pb-octreotate Analogs
SBC: RADIOMEDIX, INC. Topic: NCIA peptide receptor radionuclide therapy (PRRT) using [177Lu]/[90Y]-labeled somatostatin analogs has been proven to induce objective response in 30-45% of patients with advanced/progressive neuroendocrine tumors (NETs). The complete response to beta-emitter PRRT is rare. This is due to the fact that NETs are diagnosed at late stage of disease; the NETs patients with remissions could develop resista ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Improving Patient Outcomes through Tracking and Displaying the Disinfection Status of Equipment and Area
SBC: XENEX DISINFECTION SERVICES INC. Topic: 600Inhealthcare associated infectionsHAIswere reported in the United StatesDaily and terminal disinfection of hospital areas such as patient rooms are critically important to help prevent HAI and involve extensive disinfection of the room before a new patient is admitted to the roomAdditionallyportable medical equipmentPMEhas been implicated in outbreaks of HAIs and the importance of systematic disin ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Zinc(II) Sensitive MRI Contrast Agents as Diagnostic Sensors for Tracking Insulin Secretion
SBC: VITALQUAN LIMITED LIABILITY COMPANY Topic: NIDDKABSTRACT SignificanceDiabetes mellitus typeT Dand particularly typeT Dandgtof casesare becoming an increasing burden on socioeconomic resources with vastly increasing patient numbers all over the worldInsulin dependent treatment regimen such as regular insulin injections are well established for both T D and T D but have been associated with a negative impact on the quality of life of patients wit ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma
SBC: LEUKOGENE THERAPEUTICS INC Topic: 102Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health